Parabilis Medicines closed a $305 million Series F round to accelerate its Helicon peptide platform and advance lead candidate zolucatetide toward later‑stage testing. The financing was led by RA Capital, Fidelity and Janus Henderson and brings Parabilis significant runway to scale clinical programs. Parabilis, formerly FogPharma, is developing corkscrew‑shaped peptides designed to penetrate intracellular targets often deemed undruggable. The company said preliminary Phase 1/2 data for its lead candidates showed promising on‑target activity, prompting the large round and renewed IPO speculation by investors and executives. The funding reflects venture confidence in modalities that can reach intracellular protein surfaces; Parabilis will use proceeds to advance clinical development, manufacturing readiness and potential regulatory filings.